Introduction
============

Leukemia is a clonal disorder of hematopoietic cells that is mostly associated with genetic mutation along with a diversity of chromosomal and molecular changes.[@b1-ott-10-1793] It is one of top ten malignant tumors in China, and the number of leukemia patients has increased markedly in recent years.[@b2-ott-10-1793] Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common types of acute leukemia (AL) in both adults and children. Although there are well-documented studies of the clinical and biological aspects of leukemia, little is known about the predisposing factors of leukemia.[@b3-ott-10-1793] Smoking, obesity, and exposure to radiation and chemical carcinogens are putative or actual risk factors for AL. However, AL only develops in a small proportion of individuals who have been exposed to these environmental and lifestyle risk factors, and so the genetic background may also be a possible etiology in AL.[@b4-ott-10-1793]

NAD(P)H:quinone oxidoreductase (NQO1), which was originally called DT-diaphorase, is a flavoenzyme that can detoxify quinines derived from the oxidation of phenolic metabolites of benzene by catalyzing two or four electron reductions of these substrates. It can protect cells against oxidative damage by preventing redox cycling and the generation of free radicals.[@b5-ott-10-1793] Single-nucleotide polymorphisms (SNPs) are the most common type of variant in the human genome.[@b6-ott-10-1793] A widely researched SNP in NQO1 is C609T. A C/T change at nucleotide 609 causes a proline-to-serine substitution and therefore destabilizes and inactivates the enzyme. Individuals with TT genotype completely lack NQO1 activity, and CT genotype carriers present about threefold decreased enzyme activity compared with wild-type carriers.[@b7-ott-10-1793] The frequency of the NQO1 C609T polymorphism exhibits ethnic variation. The prevalence of the homozygous variant genotype (TT) was \~20% in Asian populations and 4% in Caucasians.[@b8-ott-10-1793] Another common SNP was C465T: a C/T change at nucleotide 465. This SNP can also diminish the activity of NQO1.[@b9-ott-10-1793] So the ability to detoxify carcinogens is reduced when these two polymorphisms are present, which may increase the probability of malignant changes in susceptible individuals.[@b10-ott-10-1793] These observations support the hypothesis that the TT genotypes for C609T or C465T polymorphisms are likely to be related to the high risk of AL.

It is possibly more meaningful to analyze the effects of genotype--environment interactions on chronic leukemia, and the genetic background may play a more important role in the etiology of AL. Since 2000, the NQO1 C609T and NQO1 C465T polymorphisms have been widely thought to be associated with the risk of AL, but the correlations are still unclear, possibly due to insufficient studies with complete data, diverse study designs and methods, differences in race and geography, and publication bias.

A meta-analysis of published case--control studies was therefore undertaken to precisely evaluate whether the NQO1 C609T and NQO1 C465T polymorphisms are associated with the risk of AL. Potential sources of heterogeneity, subgroups, stability of results, and publication bias were carefully analyzed in this study.

Methods
=======

This meta-analysis was designed and written according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Search strategy
---------------

The medical literature on associations between the AL risk and the NQO1 C609T and NQO1 C465T polymorphisms that was published before February 2016 was searched in the PubMed, EMBASE, CNKI, and Wanfang electronic databases. The following combination of keywords was used: \[AL OR (acute leukemia) OR (AML) OR (acute myeloid leukemia) OR (acute myelocytic leukemia) OR (acute myeloblastic leukemia) OR (ALL) OR (acute lymphocytic leukemia) OR (acute lymphoblastic leukemia)\] AND \[NQO1 OR (quinone reductase 1) OR (quinone oxidoreductase 1)\] AND \[polymorphism OR allele OR variant OR variation OR genotype\]. The research subjects were limited to humans, and the language was limited to English or Chinese. The references in identified publications were also browsed in order to identify any other relevant studies.

Eligibility criteria
--------------------

The following inclusion criteria were applied to the studies: 1) must focus on associations of the NQO1 C609T and NQO1 C465T polymorphisms with the AL risk; 2) must have a case--control design; and 3) the reported genotype distribution data must be sufficient to allow the odds ratios (ORs) with 95% confidence intervals (CIs) to be calculated. Studies involving larger samples or published more recently were selected in cases of repeated studies or overlapping data. If the reported data were incomplete, the corresponding author was contacted to obtain complete data.

Data extraction
---------------

The following details were extracted from all eligible studies: first author, publication year, race of included subjects, sample sizes of cases and controls, age group, genotyping method, source of controls, mutational location in NQO1, quality score, and results of the Hardy--Weinberg equilibrium (HWE) test for the controls.

Quality assessment
------------------

The quality of the included studies was assessed using the quality scoring criteria employed in a previous meta-analysis.[@b11-ott-10-1793] The representativeness of cases, source of controls, genotyping examination (whether or not genotyping was performed under a blinded condition), the association assessment method, and the HWE test for controls were included as quality assessment indicators. The quality score was calculated by summing the scores for all of these indicators, with the total score ranging from 0 to 10 points. Studies with a score of \<6 points were considered to be of low quality.

Statistical analysis
--------------------

An allele-contrast model was used to investigate the associations of the NQO1 C609T and NQO1 C465T polymorphisms with the risk of AL, and relationship strengths were assessed by ORs with 95% CIs. The statistical random-effects model was used to evaluate different underlying influences and consider variations within or among studies, which provided the advantages of accommodating diversity among studies and offering more conservative evaluations.

Heterogeneity among the studies was analyzed by the chi-square test based on the *Q* statistic, with significant heterogeneity considered to be present when the *P*-value was \<0.1. The heterogeneity was quantified by the *I*^2^ value, with a value \>50% indicating higher heterogeneity among the studies. The potential sources of heterogeneity were explored by meta-regression based on the following covariates: race, age, and source of controls. A subgroup analysis was also performed using these covariates.

The publication bias was analyzed by using funnel plots, where an asymmetric funnel plot indicates the presence of such bias. The symmetry of a funnel plot was quantified using Egger's linear regression test, where a *P*-value of \<0.05 was considered to indicate significant asymmetry and significant publication bias existence. Then the trim-and-fill method was used to assess the effect of publication bias on pooled results.

A cumulative analysis by publication year was performed to observe the trend of pooled results over time. The influence analysis of single study was applied to assess the robustness of the obtained results. Meanwhile, sensitivity analyses were also applied to studies of low quality or that did not conform to HWE to evaluate the effect of these studies on the overall results. In addition, the fail-safe number of negative studies that would be required to nullify (ie, make *P*\>0.05) the effect size was calculated, and a bigger number indicated a more stable pooled result. Stata (version 12.1) was used for all of the statistical tests.

Results
=======

Study characteristics
---------------------

In total, 893 articles were searched in electronic databases, which resulted in the inclusion of 28 studies. Among the articles, 18 and 18 were about the associations of the NQO1 C609T polymorphism with the risks of AML and ALL, respectively, two were about the association between the NQO1 C465T polymorphism and the AML risk, and three were about the association between the NQO1 C465T polymorphism and the ALL risk. Among these studies, 11 focused on Caucasians,[@b1-ott-10-1793],[@b3-ott-10-1793],[@b12-ott-10-1793]--[@b20-ott-10-1793] 10 on Asians,[@b2-ott-10-1793],[@b9-ott-10-1793],[@b10-ott-10-1793],[@b21-ott-10-1793]--[@b27-ott-10-1793] four on mixed populations,[@b5-ott-10-1793],[@b28-ott-10-1793]--[@b30-ott-10-1793] two on Africans,[@b31-ott-10-1793],[@b32-ott-10-1793] and one on Javanese.[@b33-ott-10-1793] In terms of the genotype distribution of controls, 20 of the studies about the association between the NQO1 C609T polymorphism and the AL risk conformed with HWE,[@b1-ott-10-1793],[@b3-ott-10-1793],[@b5-ott-10-1793],[@b9-ott-10-1793],[@b12-ott-10-1793],[@b14-ott-10-1793]--[@b20-ott-10-1793],[@b22-ott-10-1793]--[@b24-ott-10-1793],[@b28-ott-10-1793],[@b30-ott-10-1793]--[@b33-ott-10-1793] while seven did not,[@b2-ott-10-1793],[@b10-ott-10-1793],[@b21-ott-10-1793],[@b25-ott-10-1793]--[@b27-ott-10-1793],[@b29-ott-10-1793] and the HWE test could not be applied to one study[@b13-ott-10-1793] because of insufficient data. Two studies of the association between the NQO1 C465T polymorphism and the AL risk conformed with HWE,[@b16-ott-10-1793],[@b9-ott-10-1793] while two did not.[@b23-ott-10-1793],[@b24-ott-10-1793] Moreover, there were two studies of low quality.[@b2-ott-10-1793],[@b13-ott-10-1793] A flow diagram of the study selection procedure is shown in [Figure 1](#f1-ott-10-1793){ref-type="fig"}, and the main characteristics of the included studies are presented in [Table 1](#t1-ott-10-1793){ref-type="table"}.

NQO1 C609T polymorphism and the ALL risk
----------------------------------------

Eighteen relevant studies were used to assess the association between the NQO1 C609T polymorphism and the ALL risk. The pooled result revealed a marginally increased risk of ALL for the NQO1 C609T polymorphism (OR =1.18, 95% CI =1.00--1.39, *P*=0.05; [Figure 2A](#f2-ott-10-1793){ref-type="fig"}). The fail-safe number was 77.03. The heterogeneity was high (*I*^2^=73.0%), but meta-regression did not reveal the potential source of this heterogeneity. In addition, an increased ALL risk for adults was found in the subgroup analysis (OR =1.71, 95% CI =1.20--2.43, *P*=0.003). The results of the subgroup analysis are presented in [Table 2](#t2-ott-10-1793){ref-type="table"}.

When attempting to identify the presence of publication bias, it is difficult to assess whether a funnel plot is symmetric merely by visual examination. Egger's linear regression test provided evidence of asymmetry (*P*=0.031). The publication bias was adjusted by the trim-and-fill method; after that, the pooled result did not change (ie, the effect size from 1.322, 95% CI =1.091--1.554, to 3.752, 95% CI =2.977--4.730; [Figure 2D](#f2-ott-10-1793){ref-type="fig"}), meaning that the analyses were stable, and moreover that future new research might not change the pooled results. In addition, the influence analysis of single study showed that the total pooled result was greatly affected by the 15 studies ([Figure 2B](#f2-ott-10-1793){ref-type="fig"}).[@b2-ott-10-1793],[@b3-ott-10-1793],[@b9-ott-10-1793],[@b10-ott-10-1793],[@b12-ott-10-1793],[@b13-ott-10-1793],[@b15-ott-10-1793],[@b16-ott-10-1793],[@b19-ott-10-1793],[@b21-ott-10-1793],[@b25-ott-10-1793],[@b28-ott-10-1793]--[@b31-ott-10-1793] Excluding any of these studies resulted in the statistically significant loss of pooled OR values. Meanwhile, the sensitivity analysis revealed that deleting two studies of low quality,[@b2-ott-10-1793],[@b13-ott-10-1793] five studies that did not conform to HWE,[@b2-ott-10-1793],[@b10-ott-10-1793],[@b21-ott-10-1793],[@b25-ott-10-1793],[@b29-ott-10-1793] or one study for which the HWE test was not applied did not change the pooled ORs,[@b13-ott-10-1793] showing that these factors did not affect the stability of the pooled results. No stable tendency was found in the cumulative analysis by publication year ([Figure 2C](#f2-ott-10-1793){ref-type="fig"}).

NQO1 C609T polymorphism and the AML risk
----------------------------------------

Eighteen relevant studies were used to assess the association between the NQO1 C609T polymorphism and the AML risk. The pooled result was not statistically significant (OR =1.11, 95% CI =0.94--1.30, *P*=0.23; [Figure 3A](#f3-ott-10-1793){ref-type="fig"}). The heterogeneity was high (*I*^2^=71.5%), and meta-regression revealed that race and the source of controls were potential sources of this heterogeneity. In addition, an increased AML risk for Asians, adults, and hospital-based control groups was found in the subgroup analysis. The results of the subgroup analysis are presented in [Table 2](#t2-ott-10-1793){ref-type="table"}. Egger's linear regression test provided evidence of symmetry (*P*=0.338, [Figure 3B](#f3-ott-10-1793){ref-type="fig"}).

NQO1 C465T polymorphism and risks of AML and ALL
------------------------------------------------

Three relevant studies assessed the association between the NQO1 C465T polymorphism and the ALL risk, of which two did not find a significant association[@b9-ott-10-1793],[@b16-ott-10-1793] and one found an increased risk of ALL for the NQO1 C465T polymorphism.[@b24-ott-10-1793] Two relevant studies researched the association between the NQO1 C465T polymorphism and the AML risk, and both of them did not a find significant association.[@b9-ott-10-1793],[@b23-ott-10-1793]

Discussion
==========

The method of meta-analysis was used in this study to integrate the published evidence on the associations of the NQO1 C609T and NQO1 C465T polymorphisms with the risk of AL. A heterogeneity evaluation, source searching, sensitivity analysis, publication bias analysis, and analysis of the stability of results were also conducted.

The NQO1 C609T polymorphism was found to be a risk factor for ALL. However, the *P*-value was only marginally significant, which may have been related to the sample size, and so a more precise result will need to be obtained in the future by using a larger sample. This polymorphism was associated with an increased ALL risk for adults. The different results for children and adults may have been due to the AL etiology differing between these two populations.[@b34-ott-10-1793] Children are generally more susceptible to environmental toxins because of their immature metabolism and their faster cell division and growth compared with adults.[@b35-ott-10-1793] This result also suggests the presence of age stratification for the AL risk, and so age-stratification studies are needed to clarify this. Moreover, this research result was very sensitive, which may be due to the number of raw studies being too small, and so more relevant studies are needed to verify the association between the NQO1 C609T polymorphism and the ALL risk in the future.

The association between the NQO1 C609T polymorphism and the ALL risk was analyzed by Li and Zhou[@b36-ott-10-1793] in four models. They found that this polymorphism increased the ALL risk in a recessive model and a model of T/T versus C/C, while no statistical significance was seen in a dominant model or a model of C/T versus C/C. Their subgroup analysis found that the NQO1 C609T polymorphism increased the ALL risk for adults in a dominant model and a model of T/T versus C/C. The allele-comparison model was used in this study, and it was found that the NQO1 C609T polymorphism increased the ALL risk, with the effect size of an increased ALL risk for adults still being significant in the subgroup analysis. Only the allele-contrast model was selected for this meta-analysis, which could avoid the reuse of data and thus reduce false positive results.

No statistically significant results were found for AML in this study. Meta-regression revealed race to be a potential source of heterogeneity. The subgroup analysis showed that the NQO1 C609T polymorphism is a risk factor for AML in Asians. The meta-analysis showed that the NQO1 C609T polymorphism is a risk factor for bladder and bowel cancer in Caucasians, but a protective factor in Asians;[@b12-ott-10-1793] these differences indicate that genetic mechanisms may differ between Asians and Caucasians. In addition, the NQO1 C609T polymorphism was a risk factor for AML when the controls were from hospitals, but there were only two raw studies involving hospital-based controls, which suggests that caution is required when interpreting this result owing to the small number of samples and the corresponding low statistical power.

The association between the NQO1 C609T polymorphism and the AML risk was analyzed by Li et al[@b4-ott-10-1793] in four models. They found that the NQO1 C609T polymorphism increased the AML risk using the recessive fixed-effects model and the model of TT versus CC. However, no statistical significance was seen in the dominant random-effects model or the model of CT versus CC. In addition, the NQO1 C609T polymorphism increased the risks of AML in adults and Asians in the subgroup analysis in the recessive random-effects model in their study. In this study, no statistically significant association was found between this SNP and the AML risk under the allele-comparison model, but significant associations were found for Asians, adults, and hospital-based control groups, which was consistent with the study by Li et al.[@b4-ott-10-1793] The main differences between this study and the two articles by Li et al[@b4-ott-10-1793],[@b36-ott-10-1793] were mainly reflected in the following two aspects: 1) this sample was larger because several raw studies were newly added and 2) the stability of pooled results was also analyzed to provide a more objective evaluation.

Only a small amount of the literature focuses on the relationships of the NQO1 C465T polymorphism with the risks of ALL and AML, which was definitely not enough the meta-analysis in this study. So the results of original articles were described.

This study was subject to three main limitations. First, leukemia is associated with several risk factors including age, previous blood disease, genetic variants, occupational hazards, chemotherapy, and exposure to viruses, X-rays, and chemicals. However, only gene polymorphisms were considered in this study. The effects of gene--environment interactions on the initiation and development of leukemia need to be analyzed further in individual patients. Second, only relevant studies published in English or Chinese were included in this study, and so there is a possibility of language bias. Third, the number of raw studies was small in some of the subgroup analyses, which could have led to overestimations of real relationships.

Conclusion
==========

The NQO1 C609T polymorphism may be associated with an increased risk of AL. T allele carriers might be more susceptible to AL and thus should pay more attention to away from environmental and lifestyle risk factors. In order to provide better guidance for clinical practice, future studies need to verify the relationships of the NQO1 C609T polymorphism with the risks of ALL and AML.
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![Flow diagram of the study selection process.\
**Abbreviations:** NQO1, NAD(P)H:quinone oxidoreductase; AL, acute leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia.](ott-10-1793Fig1){#f1-ott-10-1793}

![The associations between NQO1 C609T and the ALL risk. (**A**) Calculated ORs and 95% CIs for the association. (**B**) Sensitivity analysis via deletion of each individual study. (**C**) Cumulative meta-analysis according to publication year. (**D**) Trim-and-fill plot to correct publication bias.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** NQO1, NAD(P)H:quinone oxidoreductase; ALL, acute lymphoblastic leukemia; OR, odds ratio; CI, confidence interval.](ott-10-1793Fig2){#f2-ott-10-1793}

![The associations between NQO1 C609T and AML risk. (**A**) Calculated ORs and 95% CIs for the association. (**B**) Funnel plot for detecting publication bias.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** NQO1, NAD(P)H:quinone oxidoreductase; AML, acute myeloid leukemia; OR, odds ratio; CI, confidence interval.](ott-10-1793Fig3){#f3-ott-10-1793}

###### 

Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Year   Ethnicity   Sample size   Age    Genotyping method   Control sources     Polymorphism of NQO1   Cases    *P*-value for HWE   Quality score   
  --------------------------------------------- ------ ----------- ------------- ------ ------------------- ------------------- ---------------------- -------- ------------------- --------------- ----
  Bolufer et al[@b3-ott-10-1793]                2007   Caucasian   302\          454\   Adult               PCR-based methods   PB                     C609T    AML\                0.422           8\
                                                                   141           454                                                                            ALL                                 8

  Bonaventure et al[@b12-ott-10-1793]           2012   Caucasian   433\          441\   Children            Imputation          PB                     C609T    ALL\                0.205           8\
                                                                   51            441                                                                            AML                                 8

  Chan et al[@b33-ott-10-1793]                  2011   Javanese    185           177    Children            PCR--RFLP           PB                     C609T    ALL                 0.926           7

  Clavel et al[@b30-ott-10-1793]                2005   Mixed       219           105    Children            PCR--RFLP           HB                     C609T    ALL                 0.673           7

  de Aguiar Goncalves et al[@b28-ott-10-1793]   2012   Mixed       519\          401\   Children            PCR                 PB                     C609T    ALL\                0.057           8\
                                                                   107           401                                                                            AML                                 8

  Eguchi-Ishimae et al[@b9-ott-10-1793]         2005   Asian       103\          185\   Children            PCR--RFLP           PB                     C609T\   ALL\                0.482           7\
                                                                   103           185                                                                   C465T    AML                                 7

  Eyada et al[@b13-ott-10-1793]                 2007   Caucasian   19\           11\    NA                  PCR--RFLP           NA                     C609T    AML\                NA              3\
                                                                   13            11                                                                             ALL                                 3

  Guillem et al[@b14-ott-10-1793]               2007   Caucasian   81            64     Adult               PCR--RFLP           PB                     C609T    AML                 0.556           7

  Jia et al[@b2-ott-10-1793]                    2012   Asian       102\          150\   Adult               LDR                 HB                     C609T    AML\                0.005           5\
                                                                   48            150                                                                            ALL                                 5

  Kracht et al[@b15-ott-10-1793]                2004   Caucasian   138           190    Children            PCR                 PB                     C609T    ALL                 0.147           8

  Krajinovic et al[@b16-ott-10-1793]            2002   Caucasian   174           323    Children            PCR                 PB                     C609T\   ALL                 0.312           7\
                                                                                                                                                       C465T                                        7

  Malik et al[@b5-ott-10-1793]                  2006   Mixed       262           688    Adult               PCR--RFLP           PB                     C609T    AML                 0.295           7

  Naoe et al[@b26-ott-10-1793]                  2000   Asian       411           150    Adult               PCR                 PB                     C609T    AML                 0.037           7

  Ouerhani et al[@b31-ott-10-1793]              2013   African     100           106    Adult               PCR--RFLP           PB                     C609T    ALL                 0.155           8

  Rimando et al[@b21-ott-10-1793]               2008   Asian       60            60     Children            PCR--CTPP           PB                     C609T    ALL                 \<0.01          6

  Seedhouse et al[@b1-ott-10-1793]              2002   Caucasian   168           178    Adult               PCR--RFLP           PB                     C609T    AML                 0.12            8

  Silveira Vda et al[@b17-ott-10-1793]          2010   Caucasian   206           364    Children            PCR--RFLP           HB                     C609T    ALL                 0.218           6

  Sirma et al[@b29-ott-10-1793]                 2004   Mixed       189\          286\   Children            PCR--RFLP           PB                     C609T    ALL\                0.016           6\
                                                                   84            286                                                                            AML                                 6

  Sorour et al[@b32-ott-10-1793]                2013   African     90            60     Adult               PCR--RFLP           PB                     C609T    AML                 0.299           7

  Voso et al[@b18-ott-10-1793]                  2007   Caucasian   160           162    Adult               PCR--RFLP           PB                     C609T    AML                 0.12            8

  Yamaguti et al[@b20-ott-10-1793]              2009   Caucasian   133           133    Adult               PCR--RFLP           PB                     C609T    AML                 0.054           6

  Yamaguti et al[@b19-ott-10-1793]              2010   Caucasian   99            99     Children            PCR                 PB                     C609T    ALL                 0.133           6

  Yang et al[@b22-ott-10-1793]                  2005   Asian       228           241    Adult               PCR--RFLP           PB                     C609T    AML                 0.495           6

  Zaker et al[@b23-ott-10-1793]                 2011   Asian       140           160    Adult               PCR--RFLP           PB                     C609T\   AML                 0.19\           9\
                                                                                                                                                       C465T                        \<0.01          8

  Zaker et al[@b24-ott-10-1793]                 2012   Asian       100           135    Children            PCR--RFLP           PB                     C609T\   ALL                 0.162\          8\
                                                                                                                                                       C465T                        \<0.01          7

  Zhang et al[@b25-ott-10-1793]                 2009   Asian       170           458    Adult               PCR--RFLP           PB                     C609T    ALL                 0.017           7

  Xu[@b10-ott-10-1793]                          2010   Asian       78\           100\   Adult               PCR--RFLP\          HB                     C609T    AML\                0.001           6\
                                                                   22            100                        PCR--LDR                                            ALL                                 6

  Yang[@b27-ott-10-1793]                        2006   Asian       306           458    Adult               PCR--RFLP           PB                     C609T    AML                 0.017           7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HWE, Hardy--Weinberg equilibrium; NQO1, NAD(P)H:quinone oxidoreductase; NA, not available; HB, hospital-based; PB, population-based; PCR, polymerase chain reaction; PCR-CTPP, PCR confronting two-pair primer; LDR, ligase detection reaction; RFLP, restriction fragment length polymorphism.

###### 

Subgroup analysis for the association of NQO1 C609T with AL risk

  Association     Factors          Subgroups    N    OR     95% CI       *P*-value[a](#tfn2-ott-10-1793){ref-type="table-fn"}   *I*^2^ (%)
  --------------- ---------------- ------------ ---- ------ ------------ ------------------------------------------------------ ------------
  C609T and ALL   Ethnicity        Caucasians   6    1.20   0.94--1.53   0.005                                                  70
                                   Asians       6    1.25   0.78--2.00   \<0.00001                                              86
                                   Mix          3    0.98   0.79--1.22   0.12                                                   32
                                   Javanese     1    1.16   0.85--1.56   NA                                                     NA
                                   African      1    1.57   1.01--2.44   NA                                                     NA
                  Age              Children     12   1.03   0.87--1.22   0.001                                                  64
                                   Adult        5    1.71   1.20--2.43   0.003                                                  75
                  Control source   PB           13   1.12   0.96--1.30   0.001                                                  63
                                   HB           4    1.59   0.83--3.05   \<0.00001                                              89
  C609T and AML   Ethnicity        Caucasians   7    1.02   0.83--1.26   0.14                                                   40
                                   Asians       7    1.34   1.03--1.74   0.0002                                                 77
                                   Mix          3    0.83   0.58--1.19   0.05                                                   66
                                   African      1    1.06   0.58--1.94   NA                                                     NA
                  Age              Children     4    0.80   0.63--1.01   0.4                                                    0
                                   Adult        13   1.19   1.00--1.42   \<0.0001                                               72
                  Control source   PB           15   1.03   0.88--1.21   \<0.0001                                               67
                                   HB           2    1.92   1.45--2.55   0.81                                                   0

**Note:**

*P*-value for heterogeneity test.

**Abbreviations:** AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; N, numbers of comparisons; NA, not available; NQO1, NAD(P)H:quinone oxidoreductase; OR, odds ratio; HB, hospital-based; PB, population-based; NA, not available.
